Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Find a clinical trial that's recruiting now
Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.
- 24,857
- trials recruiting now
- 14%
- of all US trials open to enrollment
- 52
- states with recruiting sites
A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.
Popular conditions
Showing the 40 largest recruiting trials by target enrollment in North Dakota. Use the search field to focus on a condition or drug.
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
Sanford Health
NCT04477928
Umbrella Study for Analysis of Data Related to Patients With Cancer
Tempus AI
NCT06018753
Baseline ACL Injury Risk Screening and Normative Data
Sanford Health
NCT06635668
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Insud Pharma
NCT05303636
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Merck Sharp & Dohme
NCT04165798
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
University of Wisconsin, Madison
NCT06924021
Effectiveness, Implementation, and Cost of Cognitive Processing Therapy in Prisons
University of Arkansas
NCT06923423
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
NCT06646276
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Melt Pharmaceuticals
NCT06383273
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Merck Sharp & Dohme
NCT06305754
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Tempus AI
NCT06163534
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme
NCT04728893
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
NCT07253285
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme
NCT04165070
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
Essentia Health
NCT05454189
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme
NCT02332668
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
NCT06846281
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
University of Maryland, Baltimore
NCT05615844
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
NCT05263206
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Inmagene
NCT07037901
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT05969860
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities
Elute
NCT05361941
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Amgen
NCT06898957
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics
NCT07217015
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Janssen Research & Development
NCT07230860
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics
NCT07187531
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
Sanford Health
NCT03858231
Contoura With Phorcides Compared to Wavefront Optimized LASIK
Daniel Terveen
NCT05486546
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Boehringer Ingelheim
NCT06624670
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Merck Sharp & Dohme
NCT06731907
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06395103
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
SFA Therapeutics
NCT05642182
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Washington University School of Medicine
NCT04966481
Midwest Birth Outcomes and Indigenous American Pregnancy
Sanford Health
NCT06008561
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
Sanford Health
NCT06883266
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
Krystal Biotech
NCT06999733
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06941272
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
Galderma R&D
NCT07074977
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
LAPIX Therapeutics
NCT06982352
Read our methodology - how recruiting status is sourced and refreshed from the public registry.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.